Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment
Artikel Sidebar
-
COPD, Roflumilast, phosphodiesterase-4 inhibitor, treatment
Abstrak
Abstract
Â
Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway inflammation with resulting progressive airflow limitation that has a high incidence, morbidity, and mortality. Roflumilast is an oral phosphodiesterase-4 inhibitor as a therapy to decrease the risk of COPD exacerbations in patients with moderate-severe COPD with a history of chronic bronchitis. Roflumilast can be given orally once daily as a single or combination drug. It can be used as COPD moderate-severe but also more beneficial as COPD mild treatment. The efficacy of Roflumilast can prevent exacerbations of repetition and can fixed lung function both in terms of FEV1 and vital capacity to force. The incidence of side effects, which are diarrhea and digestive disorders. The cost-effectiveness showed that Quality of life patient with Roflumilast is better than the group without additional. This paper aimed to review systematically Roflumilast as COPD treatment for the clinical application.
Keywords                  : COPD, Roflumilast, phosphodiesterase-4 inhibitor
Correspondence         : fauna@staff.ubaya.ac.id
Artikel teks lengkap
Referensi
REFERENCES
AgustÃ, A., & Hogg, J. C. (2019). Update on the pathogenesis of chronic obstructive pulmonary disease. New England Journal of Medicine, 381(13), 1248–1256. https://doi.org/10.1056/NEJMra1900475
Andarian, S. J., Olyaeemanesh, A., Hosseini, S. A., Sari, A. A., Firoozbakhsh, S., Jadesi, M. N., & Mobinizadeh, M. (2016). The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials. Medical Journal of the Islamic Republic of Iran, 30(1).
Berg, K., & Wright, J. L. (2016). The pathology of chronic obstructive pulmonary disease: Progress in the 20th and 21st centuries. Archives of Pathology and Laboratory Medicine, 140(12), 1423–1428. https://doi.org/10.5858/arpa.2015-0455-RS
Centers for Disease Control and Prevention (US). (2010). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US).
Cilli, A., Bal, H., & Gunen, H. (2019). Efficacy and safety profile of roflumilast in a real-world experience. Journal of Thoracic Disease, 11(4), 1100–1105. https://doi.org/10.21037/jtd.2019.04.49
Dasar, R. K. (2013). Penyajian Pokok-Pokok Hasil Riset Kesehatan Dasar 2013.
Giembycz, M. A., & Field, S. K. (2010). Roflumilast: First phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Design, Development and Therapy, 4, 147–158. https://doi.org/10.2147/dddt.s7667
Global Initiative for Chronic Obstructive Lung Disease. (2019). GOLD Pocket Guide 2019. Gold, 1–49.
GOLD. (2017). Global Initiative for Chronic Obstructive. GOLD, Global Obstructive Lung Disease, 1–44. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf
Hertel, N., Kotchie, R. W., Samyshkin, Y., Radford, M., Humphreys, S., & Jameson, K. (2012a). Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: A fully incremental analysis. International Journal of COPD, 7, 183–199. https://doi.org/10.2147/COPD.S29820
Hertel, N., Kotchie, Samyshkin, Radford, Humphreys, & Jameson. (2012b). Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. International Journal of Chronic Obstructive Pulmonary Disease, 183. https://doi.org/10.2147/COPD.S29820
King, P. T. (2015). Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clinical and Translational Medicine, 4(1), 26. https://doi.org/10.1186/s40169-015-0068-z
Lee, J. S., Hong, Y. K., Park, T. S., Lee, S. W., Oh, Y. M., & Lee, S. Do. (2016). Efficacy and safety of roflumilast in Korean patients with COPD. Yonsei Medical Journal, 57(4), 928–935. https://doi.org/10.3349/ymj.2016.57.4.928
Liu, D. Y., Wang, Z. G., Gao, Y., Zhang, H. M., Zhang, Y. X., Wang, X. J., & Peng, D. (2018). Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients. Medicine (United States), 97(7), 2–5. https://doi.org/10.1097/MD.0000000000009864
Nowak, D., Ehlken, B., Kotchie, R., Wecht, S., & Magnussen, H. (2013). Roflumilast in Kombination mit langwirksamen Bronchodilatatoren in der Versorgung von Patienten mit schwerer und sehr schwerer COPD: Eine Kosten-Effektivitäts-Analyse für Deutschland. Deutsche Medizinische Wochenschrift, 138(4), 119–125. https://doi.org/10.1055/s-0032-1327416
Pedoman Diagnosis dan Penatalaksanaan Asma di Indonesia. (2003).
Samyshkin, Y., Kotchie, R. W., Mörk, A. C., Briggs, A. H., & Bateman, E. D. (2014). Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. European Journal of Health Economics, 15(1), 69–82. https://doi.org/10.1007/s10198-013-0456-5
Samyshkin, Y., Schlunegger, Haefliger, Ledderhose, & Radford. (2013). Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. International Journal of Chronic Obstructive Pulmonary Disease, 79. https://doi.org/10.2147/COPD.S37486
Sisson, T. H., Christensen, P. J., Muraki, Y., Dils, A. J., Chibucos, L., Subbotina, N., Tohyama, K., Horowitz, J. C., Matsuo, T., Bailie, M., Nikam, S., & Hazama, M. (2018). Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury. Physiological Reports, 6(12), 1–15. https://doi.org/10.14814/phy2.13753
van der Schans, S., Goossens, L. M. A., Boland, M. R. S., Kocks, J. W. H., Postma, M. J., van Boven, J. F. M., & Rutten-van Mölken, M. P. M. H. (2017). Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. PharmacoEconomics, 35(1), 43–63. https://doi.org/10.1007/s40273-016-0448-2
Wedzicha, J. A., Calverley, P. M., & Rabe, K. F. (2016). Roflumilast: A review of its use in the treatment of COPD. International Journal of COPD, 11, 81–90. https://doi.org/10.2147/COPD.S89849
Zhang, X., Chen, Y., Fan, L., Ye, J., Fan, J., Xu, X., You, D., Liu, S., Chen, X., & Luo, P. (2018). Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap. Drug Design, Development and Therapy, 12, 2371–2379. https://doi.org/10.2147/DDDT.S165161
Zuo, H., Cattani-Cavalieri, I., Musheshe, N., Nikolaev, V. O., & Schmidt, M. (2019). Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacology and Therapeutics, 197, 225–242. https://doi.org/10.1016/j.pharmthera.2019.02.002
Penulis
Qanun Medika oleh FK UM Surabaya disebarluaskan di bawah Lisensi Creative Commons Atribusi 4.0 Internasional.
Berdasarkan ciptaan pada http://journal.um-surabaya.ac.id/index.php/qanunmedika.